Viral persistence in vivo through selection of neutralizing antibody-escape variants. - Wikidata - wikimedia - TriplyDB

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

http://www.wikidata.org/entity/Q35080884

about

Viral quasispecies evolution Impaired antibody response causes persistence of prototypic T cell-contained virus Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C Cellular immune responses against hepatitis C virus: the evidence base 2002 The impact of T cell intrinsic antigen adaptation on peripheral immune tolerance.Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters "Negative vaccination" by specific CD4 T cell tolerisation enhances virus-specific protective antibody responses Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B- and T-cell epitopes: worldwide survey.Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.Studies of human antiviral CD8+ lymphocytes using class I peptide tetramers.Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins Public versus personal serotypes of a viral quasispecies.HCV immunology--death and the maiden T cell.Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses.Protracted course of lymphocytic choriomeningitis virus WE infection in early life: induction but limited expansion of CD8+ effector T cells and absence of memory CD8+ T cells.Lassa virus.Neutralizing antibody response during acute and chronic hepatitis C virus infection Neutralizing antibodies in hepatitis C virus infection.Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.Elimination of chronic viral infection by blocking CD27 signaling.Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus.Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants.Translating insights from persistent LCMV infection into anti-HIV immunity.Antiviral antibody responses: the two extremes of a wide spectrum.Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies CD4+ T cell responses in hepatitis C virus infection.New variant of varicella-zoster virus.Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection.Kinetics of protective antibodies are determined by the viral surface antigen.Hepatitis B Virus e Antigen Regulates Monocyte Function and Promotes B Lymphocyte Activation.Genetic conflicts: the usual suspects and beyond.Role of CD27/CD70 pathway of activation in immunity and tolerance.Effect of multiple infection of cells on the evolutionary dynamics of HIV in vivo: implications for host adaptation mechanisms.Immunological memory ≠ protective immunity.Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions.Lymphocytic choriomeningitis virus (LCMV): propagation, quantitation, and storage.Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

P2860

Q27013917-70107C23-0BA3-431A-B3EB-FFF5B70358F1 Q27331309-9B447CB3-B9B3-4090-92F7-6936D60C1F34 Q27469800-6E8BCF5B-D7C8-4D53-98F9-77876D3B6DDD Q27478257-5A47F0C4-A7F7-43F8-9802-F09D11939A0B Q27480725-8EF1D5AF-AFC1-4C1E-81BA-1F06136B571A Q33260750-7416703A-ADD6-41B4-BA86-009C4A1DC860 Q33262275-CEA8EAA2-B266-42F9-9E12-BDF002CB558F Q33305432-2453A6A0-DA77-40AA-8409-C3B6AC48D141 Q33721975-51ED6973-FF05-4D03-9CBB-AA3A11B424B5 Q34057878-3906AD3D-4D60-4E5C-A436-CC291152C7EC Q34176576-CE3C604D-2D13-4198-90E5-B5D7A6E8F99C Q34301728-054AEE55-09EA-42D5-98F1-887F7FE1F333 Q34464860-010E3049-66EC-40A2-8CE5-84495B77AE4E Q34651454-D6A7D205-73BD-4D6A-B142-959E82132DAC Q35022653-BBB78E86-71F3-4C66-920B-D9AA245D2977 Q35091469-B7D03637-17E6-4728-981A-D009B009491A Q35891788-9568E0E0-B23B-4C92-8E2C-6A0CDBF5476D Q35914479-A87F1C87-655C-447C-AB97-A10048FEF633 Q35919691-3DF94156-2B5B-4837-AD33-62F048004967 Q35971609-692AEC18-3D36-4F4C-81FD-E72D14648C07 Q36179699-C15BFE07-D87E-4428-AA5D-3A0C89D6A99C Q36228781-6BFD2D43-2A74-41DA-9BF5-D345BA53A677 Q36228882-55A909E8-40CD-4799-B203-8588FC66ED31 Q36314976-B344AD64-6EBB-4F6C-97DE-12E52309EBB3 Q36376194-02EA1051-1020-4303-BF66-27A622DC3E20 Q36378994-3EC975F3-0EC0-46C4-B203-B605014630EB Q36405084-D5CDE0DB-57BC-459F-A203-F7AEB9311BDA Q36689886-564DF450-3FD9-428B-9C7D-0C22F27E627C Q36935527-7B769FDE-0E03-4C37-A5DB-C47F9A9DC584 Q37334450-471AE952-4400-4824-838C-4BFFCAFBAB39 Q37471226-D7ED9683-A6FC-49C7-8145-479581E1FF2D Q37532751-9BB3692F-4BBE-415E-9E4B-FE8E0BAEE6E5 Q37571886-60807490-2777-4AA0-B6C1-BF53B044B8A3 Q37612803-B14438F8-65EE-4828-9998-E9B83ED7EC11 Q37779170-339AD34D-01AA-4C49-B7D5-E85DAFE4B8E7 Q37902370-AFDCB770-9E35-4BAB-831C-2ED58E358A83 Q38000488-E1A953BD-381B-4C21-A134-8B5B4C946C30 Q38064285-83814BE2-839E-4A03-9F62-527A8F04F285 Q39246396-6A775A30-7C81-4193-8ED8-6762E43AA7AD Q39605628-69E1B1CD-6B43-4BAD-9144-74858DAEC800

P2860

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

http://www.wikidata.org/entity/Q35080884

description

2000 nî lūn-bûn

@nan

2000 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մարտին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

@ast

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

@en

type

label

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

@ast

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

@en

prefLabel

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

@ast

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

@en

P1433

Q35080884-3B8C09C7-4F17-4274-9E6A-04B3724A7B32

P1476

Q35080884-BFC1FFE7-C5DC-490E-A7B9-B3AAF958A6A7

P2093

Q35080884-39669ED0-C39E-42D1-8606-D8A47009190F

Q35080884-B9864544-9252-4287-A434-6635AFA0FABC

Q35080884-BFE0BBEC-D513-4360-BA75-1BE79432493E

Q35080884-D6F764CE-0B5C-4A9C-BBAC-C297762DDE1F

Q35080884-E063D9E3-133E-4D75-A127-8A2CA546AEEA

Q35080884-E1DFF114-B3A6-467A-909F-2FDDCEC6CB77

P2860

Q35080884-05E110D2-CA53-41E5-B9D7-6A72CDC14891

Q35080884-0B8BEA0C-9452-4181-8C02-5CA076B70A8A

Q35080884-0DC7E043-C493-472C-8601-DF15870F1CDE

Q35080884-0E74C616-6BCE-431F-AADE-BD2B7D246DDE

Q35080884-1136A0B9-C215-4F66-9BF8-F5255348527C

Q35080884-1C51EC75-A9FE-490C-A076-D6E5AEDDCA17

Q35080884-21772DCD-6FC0-4F07-AC73-521B3B486797

Q35080884-3120508C-BB5F-4203-977B-8DC62B5444EE

Q35080884-37789D5C-F2F4-418B-BD05-4A4F700F2182

Q35080884-47F1B122-C737-4746-B18A-9B80FF41FD3C

P304

Q35080884-E2E24741-91A3-4400-A1EA-4968EFF88ACE

P31

Q35080884-D5331F26-E602-44A1-B0A0-C9AC69137AB2

P356

Q35080884-C9280BB3-5347-4EE0-B902-1C61C074A510

P407

Q35080884-04B3841E-704A-4A45-8924-40CE4915FF82

P433

Q35080884-2333CBB8-CD24-4598-A7B9-C6CE84C43FF6

P478

Q35080884-F2D7F3C0-AAF2-4080-B002-28C32D0DB677

P50

Q35080884-26771553-5C36-46B1-98E3-C3A9C7BD8E54

Q35080884-4EED00BE-29F9-4D0F-860C-3885F39140FE

P577

Q35080884-573ABEE7-22C9-4650-82C9-F8EF398C0B5F

P5875

Q35080884-68F24EAB-2BCF-41FD-B665-0638A1BEBADA

P698

Q35080884-526AACB9-9D62-4AB1-A2BC-F271CC78B963

P921

Q35080884-3FB68027-B976-42D2-B5B9-57336E4BA82B

Q35080884-AD855C87-B8DE-4141-8905-BE78957B2470

P932

Q35080884-81CCFA78-4EEC-46B9-9C90-C3E67919F109

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Viral persistence in vivo through selection of neutralizing antibody-escape variants

@en

P2093

Hengartner H

http://www.w3.org/2001/XMLSchema#string

Horvath E

http://www.w3.org/2001/XMLSchema#string

Klenerman P

http://www.w3.org/2001/XMLSchema#string

Ochsenbein AF

http://www.w3.org/2001/XMLSchema#string

Senn BM

http://www.w3.org/2001/XMLSchema#string

Zinkernagel RM

http://www.w3.org/2001/XMLSchema#string

P2860

Functional role of type I and type II interferons in antiviral defense

Viral immune evasion due to persistence of activated T cells without effector function

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

Enhanced virus clearance by early inducible lymphocytic choriomeningitis virus-neutralizing antibodies in immunoglobulin-transgenic mice

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice.

Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells.

P304

2749-2754

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.040558797

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

2000-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12626452

http://www.w3.org/2001/XMLSchema#string

P698

10688894

http://www.w3.org/2001/XMLSchema#string

P921

viral persistence

P932

16001

http://www.w3.org/2001/XMLSchema#string